Developing Next-Generation Neuroactive Medicines for Mood and Anxiety Disorders
Lophora is a clinical-stage CNS therapeutics company developing differentiated, next-generation neuroactive medicines designed to induce neuroplasticity and address significant unmet needs in neuropsychiatry
Company
Lophora has identified and patented a new class of proprietary ligands. The company’s lead compound, LPH-5, is a highly selective small-molecule agonist of the serotonin 5-HT2A receptor with robust CNS exposure and demonstrated target engagement. In preclinical models, LPH-5 has shown activity at sub-perceptual (non-psychedelic) dose levels. LPH-5 has completed dosing in a Phase I clinical trial, with early read-outs indicating a favourable safety and tolerability profile, supporting its potential suitability for multiple-dosing paradigms.
To stay informed about upcoming results and company developments, sign up for Lophora Insights below.
Lophora Announces Positive Phase 1 Topline Results for LPH-5
First-in-human single ascending dose study supports continued development of LPH-5 toward a scalable at-home treatment for depressive disorders and other
Lophora Announces First Subjects Dosed in Phase 1 Clinical Trial of LPH-5
Lophora ApS, a Danish biotech company focused on next-generation psychedelic therapies for central nervous system disorders, today announced that the
Lophora Successfully Completes $3M Financing to Propel Phase I Trials for Lead CNS Drug LPH-5
After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has
Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression.
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2AR therapeutics to treat psychiatric disorders, announced today that
People
Lophora is led by an experienced executive team with a strong scientific and commercial track record, backed by a board and advisors with decades of CNS drug development experience.
Request investor deck
Science & Pipeline
Lophora’s drug design platform is built on rational engineering of 5-HT2A agonists with optimized drug-like properties and reduced off-target activity.
LPH-5 is now in first-in-human evaluation, with LPH-48 and additional NCE candidates in expansion.
- Stage: Entering Phase II (LPH-5)
- Latest financing: $3M (Jan 2025)
- Lead asset: LPH-5 — selective 5-HT2A agonist
- Second asset: LPH-48 — pre-clinical fast-follower
- IP position: Composition of matter granted US/EU/CN/JP etc.
- Pipeline: Expandable NCE program targeting CNS indications
Investors
Lophora is funded by BII (Novo Nordisk Foundation), Innovation Fund Denmark, Export and Investment Fund of Denmark (EIFO), family offices and experienced biotech investors such as Don deBethizy (USA) and Tim Haines (UK).